Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 152

Related Citations for PubMed (Select 23367674)

1.

Roflumilast: doubtful efficacy but clear harms in COPD.

[No authors listed]

Prescrire Int. 2013 Jan;22(134):5-9.

PMID:
23367674
2.

Clinical Considerations for Roflumilast: A New Treatment for COPD.

Kelly Freeman ML.

Consult Pharm. 2012 Mar;27(3):189-93. doi: 10.4141/TCP.n.2012.189.

PMID:
22421519
3.

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Pinner NA, Hamilton LA, Hughes A.

Clin Ther. 2012 Jan;34(1):56-66. doi: 10.1016/j.clinthera.2011.12.008. Review.

PMID:
22284994
4.

Roflumilast in the management of chronic obstructive pulmonary disease.

Lipari M, Benipal H, Kale-Pradhan P.

Am J Health Syst Pharm. 2013 Dec 1;70(23):2087-95. doi: 10.2146/ajhp130114. Review.

PMID:
24249758
5.

Efficacy of roflumilast in the COPD frequent exacerbator phenotype.

Wedzicha JA, Rabe KF, Martinez FJ, Bredenbröker D, Brose M, Goehring UM, Calverley PM.

Chest. 2013 May;143(5):1302-11. doi: 10.1378/chest.12-1489.

PMID:
23117188
6.

Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.

Giembycz MA, Field SK.

Drug Des Devel Ther. 2010 Jul 21;4:147-58. Review.

7.

Roflumilast: a novel treatment for chronic obstructive pulmonary disease.

Reid DJ, Pham NT.

Ann Pharmacother. 2012 Apr;46(4):521-9. doi: 10.1345/aph.1Q646. Epub 2012 Mar 20. Review.

PMID:
22433610
8.

Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, Rabe KF.

Int J Chron Obstruct Pulmon Dis. 2012;7:375-82. doi: 10.2147/COPD.S31100. Epub 2012 Jun 20.

9.

Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.

Rabe KF.

Br J Pharmacol. 2011 May;163(1):53-67. doi: 10.1111/j.1476-5381.2011.01218.x. Review.

10.

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ.

Respir Res. 2011 Jan 27;12:18. doi: 10.1186/1465-9921-12-18.

11.

A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.

Rutten-van Mölken MP, van Nooten FE, Lindemann M, Caeser M, Calverley PM.

Pharmacoeconomics. 2007;25(8):695-711.

PMID:
17640111
12.

Roflumilast for COPD.

Izquierdo JL, Aparicio J.

Drugs Today (Barc). 2010 Nov;46(11):823-31. doi: 10.1358/dot.2010.46.11.1521831. Review.

PMID:
21225021
13.

Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.

Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA.

Swiss Med Wkly. 2012 Jul 25;142:w13628. doi: 10.4414/smw.2012.13628. Review.

14.

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups.

Lancet. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: Lancet. 2010 Oct 2;376(9747):1146.

PMID:
19716960
15.

Reduce disease burden and improve lung function-roflumilast: approved for moderate to severe COPD: update for the clinical nurse specialist.

O'Malley P.

Clin Nurse Spec. 2011 Jul-Aug;25(4):176-7. doi: 10.1097/NUR.0b013e31822229a9. No abstract available.

PMID:
21654371
16.

Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor.

Gross NJ, Giembycz MA, Rennard SI.

COPD. 2010 Apr;7(2):141-53. doi: 10.3109/15412551003758304. Review.

PMID:
20397815
17.

The use of roflumilast in COPD: a primary care perspective.

Price D, Chisholm A, Ryan D, Crockett A, Jones R.

Prim Care Respir J. 2010 Dec;19(4):342-51. doi: 10.4104/pcrj.2010.00066. Review. Erratum in: Prim Care Respir J. 2011 Mar;20(1):45.

18.

Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis.

Yan JH, Gu WJ, Pan L.

Pulm Pharmacol Ther. 2014 Feb;27(1):83-9. doi: 10.1016/j.pupt.2013.04.004. Epub 2013 Apr 23.

PMID:
23624309
19.

Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.

Tashkin DP.

Expert Opin Pharmacother. 2014 Jan;15(1):85-96. doi: 10.1517/14656566.2013.837159. Epub 2013 Sep 14. Review.

PMID:
24032576
20.

The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.

Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, Tenor H.

Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. doi: 10.1016/j.pupt.2010.03.011. Epub 2010 Apr 7. Review.

PMID:
20381629
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk